Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

<tt>edgeR</tt> : a Bioconductor package for differential expression analysis of digital gene expression data

Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364

limma powers differential expression analyses for RNA-sequencing and microarray studies

Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458

ggplot2

Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 34,873

Integrative genomics viewer

Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390

ggplot2: Elegant Graphics for Data Analysis

Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053

DNMT3A Mutations in Acute Myeloid Leukemia

Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983

Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function

Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978

A human memory T cell subset with stem cell–like properties

Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,847

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,842

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion

Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646

Transcriptional control of effector and memory CD8+ T cell differentiation

Kaech, S. M., & Cui, W. (2012) · Nature Reviews Immunology · doi:10.1038/nri3307 · Cited by 1,628

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

Pauken, K. E., Sammons, M. A., Odorizzi, P. M., Manne, S., Godec, J., Khan, O., Drake, A. M., Chen, Z., Sen, D. R., Kurachi, M., et al. (2016) · Science · doi:10.1126/science.aaf2807 · Cited by 1,348

Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells

Moskophidis, D., Lechner, F., Pircher, H., & Zinkernagel, R. M. (1993) · Nature · doi:10.1038/362758a0 · Cited by 1,240

BSMAP: whole genome bisulfite sequence MAPping program

Xi, Y., & Li, W. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-232 · Cited by 1,216

TOX is a critical regulator of tumour-specific T cell differentiation

Scott, A. C., Dündar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1324-y · Cited by 1,106

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004

The epigenetic landscape of T cell exhaustion

Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986

Interleukin-10 determines viral clearance or persistence in vivo

Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 937

TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection

Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H. E., Roelli, P., Utzschneider, D. T., von Hoesslin, M., Cullen, J. G., Fan, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1326-9 · Cited by 930

c-Jun overexpression in CAR T cells induces exhaustion resistance

Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891 · cited 2×

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 888

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

Imai, C., Mihara, K., Andreánsky, M., Nicholson, I., Pui, C., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 844

De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation

Ghoneim, H. E., Fan, Y., Moustaki, A., Abdelsamed, H. A., Dash, P., Dogra, P., Carter, R., Awad, W., Neale, G. A. M., Thomas, P. G., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.007 · Cited by 808

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Feucht, J., Sun, J., Eyquem, J., Ho, Y.-J., Zhao, Z., Leibold, J., Dobrin, A., Cabriolu, A., Hamieh, M., & Sadelain, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0290-5 · Cited by 547

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

Krishna, S., Lowery, F. J., Copeland, A. R., Bahadiroglu, E., Mukherjee, R., Jia, L., Anibal, J., Sachs, A., Adebola, S. O., Gurusamy, D., et al. (2020) · Science · doi:10.1126/science.abb9847 · Cited by 546

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

Heczey, A. A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A. G., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A. P., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527

Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18

Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 516

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Beatty, G. L., O’Hara, M. H., Lacey, S. F., Torigian, D. A., Nazimuddin, F., Chen, F., Kulikovskaya, I. M., Soulen, M. C., McGarvey, M., Nelson, A. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.029 · Cited by 516

Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells

Liao, J., Karnik, R., Gu, H., Ziller, M. J., Clement, K., Tsankov, A. M., Akopian, V., Gifford, C. A., Donaghey, J., Galonska, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3258 · Cited by 497

Effector CD8 T cells dedifferentiate into long-lived memory cells

Youngblood, B., Hale, J. S., Kissick, H. T., Ahn, E., Xu, X., Wieland, A., Araki, K., West, E. E., Ghoneim, H. E., Fan, Y., et al. (2017) · Nature · doi:10.1038/nature25144 · Cited by 496

Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

Guo, Y., Xie, Y., Gao, M., Zhao, Y., Franco, F., Wenes, M., Siddiqui, I., Bevilacqua, A., Wang, H., Yang, H., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00940-2 · Cited by 455

Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells

Youngblood, B., Oestreich, K. J., Ha, S., Duraiswamy, J., Akondy, R. S., West, E. E., Wei, Z., Lu, P., Austin, J. W., Riley, J. L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.015 · Cited by 418

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M. R., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2034-7 · Cited by 413

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

Park, J. H., Geyer, M. B., & Brentjens, R. J. (2016) · Blood · doi:10.1182/blood-2016-02-629063 · Cited by 411

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia

Mueller, K. T., Maude, S. L., Porter, D. L., Frey, N. V., Wood, P. A., Han, X., Waldron, E. K., Chakraborty, A., Awasthi, R., Levine, B. L., et al. (2017) · Blood · doi:10.1182/blood-2017-06-786129 · Cited by 367

Detection of differentially methylated regions from whole-genome bisulfite sequencing data without replicates

Wu, H., Xu, T., Feng, H., Chen, L., Li, B., Yao, B., Qin, Z. S., Jin, P., & Conneely, K. N. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv715 · Cited by 359

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

Krenciute, G., Prinzing, B. L., Yi, Z., Wu, M.-F., Liu, H., Dotti, G., Balyasnikova, I. V., & Gottschalk, S. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0376 · Cited by 328

BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers

Roychoudhuri, R., Clever, D. C., Li, P., Wakabayashi, Y., Quinn, K. M., Klebanoff, C. A., Ji, Y., Sukumar, M., Eil, R. L., Yu, Z., et al. (2016) · Nature Immunology · doi:10.1038/ni.3441 · Cited by 317

MOABS: model based analysis of bisulfite sequencing data

Sun, D., Xi, Y., Rodriguez, B. A. T., Park, H. J., Tong, P., Meong, M., Goodell, M. A., & Li, W. (2014) · Genome biology · doi:10.1186/gb-2014-15-2-r38 · Cited by 295

Developmental plasticity allows outside-in immune responses by resident memory T cells

Fonseca, R., Beura, L. K., Quarnstrom, C. F., Ghoneim, H. E., Fan, Y., Zebley, C. C., Scott, M. C., Fares-Frederickson, N. J., Wijeyesinghe, S., Thompson, E. A., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0607-7 · Cited by 286

T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma

Chow, K. K. H., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N. C., Wu, M.-F., Liu, H., Kew, Y., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 244

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity

Ghosh, A., Smith, M. M., James, S. E., Davila, M. L., Velardi, E., Argyropoulos, K. V., Gunset, G., Perna, F., Kreines, F. M., Levy, E. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4258 · Cited by 217

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.133 · Cited by 215

Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function

Scharer, C. D., Barwick, B. G., Youngblood, B., Ahmed, R., & Boss, J. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301395 · Cited by 212

Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ

Fujii, S., Shimizu, K., Shimizu, T., & Lotze, M. T. (2001) · Blood · doi:10.1182/blood.v98.7.2143 · Cited by 208

Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells

Ahmed, N. M., Ratnayake, M., Savoldo, B., Perlaky, L., Dotti, G., Wels, W. S., Bhattacharjee, M. B., Gilbertson, R. J., Shine, H. D., Weiss, H. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4309 · Cited by 192

Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

Mata, M., Gerken, C. P., Nguyen, P., Krenciute, G., Spencer, D. M., & Gottschalk, S. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0263 · Cited by 181

CRIS.py: A Versatile and High-throughput Analysis Program for CRISPR-based Genome Editing

Connelly, J. P., & Pruett‐Miller, S. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-40896-w · Cited by 174

Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells

Youngblood, B., Noto, A., Porichis, F., Akondy, R. S., Ndhlovu, Z. M., Austin, J. W., Bordi, R., Procopio, F. A., Miura, T., Allen, T. M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203161 · Cited by 169

T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies

Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K. H., Kakarla, S., Spencer, D. M., Dotti, G., Wu, M.-F., Liu, H., Kenney, S. C., et al. (2011) · Blood · doi:10.1182/blood-2010-04-278218 · Cited by 165

Transcriptional and Epigenetic Regulation of Effector and Memory CD8 T Cell Differentiation

Chen, Y., Zander, R., Khatun, A., Schauder, D., & Cui, W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02826 · Cited by 156

Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis

Abdelsamed, H. A., Moustaki, A., Fan, Y., Dogra, P., Ghoneim, H. E., Zebley, C. C., Triplett, B. M., Sékaly, R., & Youngblood, B. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161760 · Cited by 147

Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia

Iacobucci, I., Li, Y., Roberts, K. G., Dobson, S. M., Kim, J. C., Payne-Turner, D., Harvey, R. C., Valentine, M. L., McCastlain, K., Easton, J. B., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.013 · Cited by 146

Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

Yi, Z., Prinzing, B. L., Cao, F., Gottschalk, S. M., & Krenciute, G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.009 · Cited by 125

Beta cell-specific CD8+ T cells maintain stem cell memory-associated epigenetic programs during type 1 diabetes

Abdelsamed, H. A., Zebley, C. C., Nguyen, H., Rutishauser, R. L., Fan, Y., Ghoneim, H. E., Crawford, J. C., Alfei, F., Alli, S., Ribeiro, S. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0633-5 · Cited by 121

Pathway-Based Genomics Prediction using Generalized Elastic Net

Sokolov, A., Carlin, D. E., Paull, E., Baertsch, R., & Stuart, J. M. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004790 · Cited by 112

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

Li, W., Guo, L., Rathi, P., Marinova, E., Gao, X., Wu, M.-F., Liu, H., Dotti, G., Gottschalk, S. M., Metelitsa, L. S., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.025 · Cited by 109

Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media

Bauler, M. N., Roberts, J. K., Wu, C., Fan, B., Ferrara, F., Yip, B. H., Diao, S., Kim, Y., Moore, J., Zhou, S., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.011 · Cited by 105

Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion

Ahn, E., Youngblood, B., Lee, J., Lee, J., Sarkar, S., & Ahmed, R. (2016) · Journal of Virology · doi:10.1128/jvi.00798-16 · Cited by 95

Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma

Krenciute, G., Krebs, S. S., Torres, D., Wu, M.-F., Liu, H., Dotti, G., Li, X., Lesniak, M. S., Balyasnikova, I. V., & Gottschalk, S. M. (2015) · Molecular Therapy · doi:10.1038/mt.2015.199 · Cited by 90

Driving CAR T cell translation forward

Schultz, L. M., & Mackall, C. L. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2127 · Cited by 81

Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy

Zebley, C. C., Gottschalk, S. M., & Youngblood, B. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.008 · Cited by 71

Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells.

Youngblood, B., Wherry, E. J., & Ahmed, R. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834ddcf2 · Cited by 68

A Chimeric GM-CSF/IL18 Receptor to Sustain CAR T-cell Function

Lange, S., Sand, L. G. L., Bell, M., Patil, S. L., Langfitt, D., & Gottschalk, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0896 · Cited by 68

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies

Velasquez, M. P., Torres, D., Iwahori, K., Kakarla, S., Arber, C., Rodríguez-Cruz, T., Szöőr, Á., Bonifant, C. L., Gerken, C. P., Cooper, L. J. N., et al. (2016) · Scientific Reports · doi:10.1038/srep27130 · Cited by 59

Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity

Chan, W. K., Suwannasaen, D., Throm, R. E., Li, Y., Eldridge, P. W., Houston, J., Gray, J. T., Pui, C.-H., & Leung, W. H. (2014) · Leukemia · doi:10.1038/leu.2014.174 · Cited by 55

Dnmt3a regulates T-cell development and suppresses T-ALL transformation

Kramer, A. C., Kothari, A., Wilson, W. C., Celik, H., Nikitas, J., Mallaney, C., Ostrander, E. L., Eultgen, E., Martens, A., Valentine, M. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.89 · Cited by 53

Epigenetic Repression of Interleukin 2 Expression in Senescent CD4+T Cells During Chronic HIV Type 1 Infection

Nakayama‐Hosoya, K., Ishida, T., Youngblood, B., Nakamura, H., Hosoya, N., Koga, M., Koibuchi, T., Iwamoto, A., & Kawana‐Tachikawa, A. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu376 · Cited by 45

Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion

Tovy, A., Reyes, J. M., Gundry, M. C., Brunetti, L., Lee-Six, H., Petljak, M., Park, H. J., Guzman, A. G., Rosas, C., Jeffries, A. R., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.06.018 · Cited by 30

Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors

Chockley, P. J., Patil, S. L., & Gottschalk, S. M. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.04.010 · Cited by 22

CAR immune cells: design principles, resistance and the next generation

Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 695

CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

Albelda, S. Μ. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 561

T Cell Exhaustion

Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420

Epigenetic regulation of T cell exhaustion

Belk, J. A., Dániel, B., & Satpathy, A. T. (2022) · Nature Immunology · doi:10.1038/s41590-022-01224-z · Cited by 346

RASA2 ablation in T cells boosts antigen sensitivity and long-term function

Carnevale, J. C., Shifrut, E., Kale, N., Nyberg, W. A., Blaeschke, F., Chen, Y. Y., Li, Z., Bapat, S. P., Diolaiti, M. E., O’Leary, P. C., et al. (2022) · Nature · doi:10.1038/s41586-022-05126-w · Cited by 243

De novo DNA methylation programs regulate CAR T-cell exhaustion

Zebley, C. C., Petersen, C. T., Prinzing, B. L., Bell, M. R., Fan, Y., Crawford, J. C., Houke, H., Haydar, D., Yi, Z., Nguyen, P., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.204.supp.246.5 · Cited by 5

De novo DNA methylation programs regulate T cell exhaustion and limit T cell-based immunotherapies

Youngblood, B., Ghoneim, H. E., Abdelsamed, H. A., Moustaki, A., Fan, Y., Crawford, J. C., Thomas, P. G., Stewart, E. S., & Federico, S. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.202.supp.134.14 · Cited by 3

CAR T cells need a pitstop to win the race

Zebley, C. C., & Youngblood, B. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.011 · Cited by 5

Abstract 61: Transient "rest" reinvigorates exhausted CAR T cells via epigenetic remodeling

Weber, E. W., & Mackall, C. L. (2021) · Cancer Research · doi:10.1158/1538-7445.am2021-61

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Dániel, B., Klysz, D. D., et al. (2021) · Science · doi:10.1126/science.aba1786 · Cited by 653